First-line therapeutic strategies in metastatic colorectal cancer

ONCOLOGY

Volumn 22, Issue 13, 2008, Pages 1470-1479

  Davies, Janine M ^a   Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; PLACEBO;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSESTHESIA; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; PROTEINURIA; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; META-ANALYSIS AS TOPIC; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PYRAZOLES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VITAMIN B COMPLEX;

EID: 58049084028     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. American Cancer Society: Cancer Facts & Figures 2008. Atlanta, American Cancer Society, 2008.
2. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition staging. J Natl Cancer Inst 96:1420-1425, 2004.
3. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005.
4. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
5. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997.
6. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998.
7. Meta-Analysis Group in Cancer: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 22:3766-3775, 2004.
8. Meta-Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541, 1998.
9. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000.
10. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000.
11. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
12. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001.
13. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001.
14. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
15. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25:4779-4786, 2007.
16. Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008.
17. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005.
18. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004.
19. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23:9441-9442, 2005.
20. Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152, 2007.
21. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007.
22. Schmoll HJ, Sargent D: Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet 370:105-107, 2007.
23. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004.
24. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007.
25. Souglakos J, Androulakis N, Syrigos K, et al: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94:798-805, 2006.
26. Masi G, Allegrini G, Cupini S, et al: First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/ leucovorin (FOLFOXIRI): Results of a phase II study with a simplified biweekly schedule. Ann Oncol 15:1766-1772, 2004.
27. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24:394-400, 2006.
28. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study (abstract 4013). J Clin Oncol 25(18S):166s, 2007.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
30. Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidinies in first-fine treatment of metastatic colorectal cancer: Updated results from the BICC-C study: letter to the editor. J Clin Oncol 26:689-690, 2008.
31. Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008.
32. Berry SR, Van Cutsem E, Kretzschmar A, et al: Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT (abstract 4025). J Clin Oncol 26(15S):184s, 2008.
33. Hedrick E, Kozloff M, Hainsworth J, et al: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) (abstract 3536). J Clin Oncol 24(18S):155s, 2006.
34. Purdie DM, Berlin JD, Flynn PJ, et al: The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS) (abstract 4103). J Clin Oncol 26(15S):203s, 2008.
35. Kozloff M, Hainsworth J, Badarinath S, et al: Survival of patients (pts) with mCRC treated with bevacizumab in combination with chemotherapy: results from the BRiTE registry (abstract 375). Presented at the 2007 Gastrointestinal Cancers Symposium; Orlando, Fla; January 19-21, 2007.
36. Grothey A, Sugrue M, Hedrick E, et al: Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE) (abstract 4036). J Clin Oncol 25(18S):172s, 2007.
37. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005.
38. Ng K, Zhu AX: Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol 65:8-20, 2008.
39. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial (abstract 4000). J Clin Oncol 25(18S):164s, 2007.
40. Van Cutsem E, Lang I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience (abstract 2). J Clin Oncol 26(15S):5s, 2008.
41. Bokemeyer C, Bondarenko I, Makhson A, et al: Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) versus FOLFOX4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study (abstract 4035). J Clin Oncol 25(18S):172s, 2007.
42. Bokemeyer C, I. Bondarenko, Hartmann JT, et al: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience (abstract 4000). J Clin Oncol 26(15S):178s, 2008.
43. Siena S, Tabernero J, Burkes RL, et al: Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data (abstract 4034). J Clin Oncol 26(15S):186s, 2008.
44. Saltz LB, Lenz HJ, Kindler HL, et al: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 25:4557-4561, 2007.
45. Punt CJ, Tol J, Rodenburg CJ, et al: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIR02 study of the Dutch Colorectal Cancer Group (DCCG) (abstract LBA4011). J Clin Oncol 26(18S):1008s, 2008.
46. Tournigand C, Lledo G, Delord J, et al: Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR) (abstract 4097). J Clin Oncol 25(18S):187s, 2007.
47. Hecht JR, Mitchell E, Chidiac T, et al: An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE) (abstract 273). Presented at the 2008 Gastrointestinal Cancers Symposium; Orlando, Fla; January 25-27, 2008.
48. Hecht JR, Mitchell E, Chidiac T, et al: Interim results from PACCE: irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC) (abstract 279). Presented at the 2008 Gastrointestinal Cancers Symposium; Orlando, Fla; January 25-27, 2008.